Stock REVBU REVELATION BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News Revelation Biosciences, Inc. Nasdaq

Equities

REVBU

US76135L2007

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Revelation Biosciences : NOTICE OF EXERCISE Form 8 K
PU
Revelation Biosciences Shares Jump on Positive Results for Investigational Drug Gemini
MT
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
BU
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
CI
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
BU
Revelation Biosciences, Inc. Has Completed Dosing of Its First in Human Phase 1 Clinical Study of Gemini
CI
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
BU
Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Revelation Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
BU
Revelation Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
BU
Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference
BU
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
BU
Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
CI
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
BU
Revelation Biosciences : Announces Commencement of First in Human Phase 1 Clinical Study of Gemini
PU
Thinking about buying stock in Meta Platforms, Ocular Therapeutix, Phathom Pharmaceuticals, Revelation Biosciences, or Sunworks?
PR
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
BU
Top Midday Decliners
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. REVB Stock
  4. REVBU Stock
  5. News Revelation Biosciences, Inc.